EGFR and non-small cell lung carcinoma: EGFR has long been recognized as a therapeutic target due to the significant upregulation of EGFR expression in NSCLC.266 Following the IPASS study, which demonstrated that gefitinib was superior to double-platinum chemotherapy, six randomized and controlled trials confirmed that the objective response rate (ORR) across various EGFR TKIs ranged from 62% to 83%, median PFS from 9.2 to 13.1 months, and median OS from 21.6 to 36 months.